home All News open_in_new Full Article

Orforglipron, el nuevo fármaco que se administra por vía oral y puede abrir una nueva etapa en el tratamiento de la obesidad

Investigadores del Hospital Vall d'Hebron de Barcelona han comprobado que el medicamento reduce, de media, un 11% el peso corporal, al tiempo que mejora factores de riesgo cardiovascular Leer


today 3 h. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Events
attach_file Politics
attach_file Politics
attach_file Science
attach_file Politics
attach_file Politics
attach_file Culture
attach_file Politics
attach_file Politics
attach_file Economics


ID: 1407272562
Add Watch Country

arrow_drop_down